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Purpose: Aortic stenosis (AS) is a disease process akin to atherosclerosis
and has been linked to several risk factors for coronary artery disease (CAD).
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory
biomarker secreted in the atherosclerotic plaque. We hypothesized a relation-
ship between serum Lp-PLA2, plasma oxidized LDL (oxLDL) and AS, in
contrast with CAD.
Methods: Between December 2009 and June 2010, from 494 subjects
scheduled for diagnostic coronary angiography, we selected 234 patients
(71.2% men) included into 2 groups: Group “CAD”: patients with only CAD
and Group “AS”: patients with AS and normal coronary arteries. Lp-PLA2
mass was assessed in serum with a Plac® – test turbidimetric immunoassay.
Control Lp-PLA2 values were specifically obtained in 61 subjects aged
44.5±17.6y without cardiovascular risk factors or cardiac treatment.
Results: In healthy controls, Lp-PLA2 was 163±43 μg/L (men: 166±45 μg/L;
women: 159±39 μg/L, non significant). Lp-PLA2 were significantly higher in
patients than in controls (219.2±49.1 vs 163.0±43.0; p=0.01). Lp-PLA2
increased in AS-patients, and were not significantly different than CAD-
patients (217.3±44.5 vs. 220.4±51.9, respectively; NS). Moreover, Lp-PLA2
levels were similar in patients with single-vessel atherosclerosis (215.2±52.0)
but significantly lower than in patients with three-vessel atherosclerosis
(251.9±5.7 μg/L; p=0.03).
OxLDL levels were 42±13 U/L, which was within normal values. oxLDL
values were 46±12 and 38±12 U/L for AS-patients and CAD-patients, respec-
tively, (p<0.0001). Circulating oxLDL levels were not affected by gender, dia-
betes or hypertension but were significantly correlated with serum apoB,
LDL-cholesterol, triglycerides and ApoA-I. We found no correlation between
Lp-PLA2 and oxLDL. Patients on statin treatment had significantly lower
plasma oxLDL levels than patients without any hypolipidemic treatment.
Conclusion: We report for the first time that high serum levels of Lp-
PLA2 were associated with severe AS. This could have practical implications
because statins and renin-angiotensin-aldosteron system inhibitors seemed to
be a promising treatments of AS.
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Introduction: During Ramadan, Muslims fast during the daylight hours
for a month. A pharmacokinetic variability of several medications can
occurred in this period. However, the effect of Ramadan fasting on INR (Inter-
national normalized ratio) is unknown.
Aim of this study: was to evaluate the fasting Ramadan effect on the vari-
ability of the INR in patients treated at long term with oral anticoagulant.
Methods: 67 fasting patients (aged 60±11.4 years) treated at long term by
acenocoumarol in the evening who fasted during Ramadan participated in this
open, prospective and single center study. Venous blood samples were taken
1 week before Ramadan (INR1), on the 15st (INR2) and 29th days (INR3) of
Ramadan. Exclusion criteria was an INR1<1.7 or INR1>4.5 before Ramadan
and patient taking twice daily dose.
Results: Compared before Ramadan, the mean INR2 was significantly
increased during the 15th days of Ramadan, 4.1±1.7 vs 2.9±0.8, respectively
(p<0.001). A Vitamin K antagonist overdose (INR2>5) was obtained in
19 patients (28.4%). The mean variation of INR2 during this first period was
+46.5% (–35%, +256.4%). We excluded for the third measure all patients with
an INR2>5. The mean INR3 (n=42 pts) was significantly higher than the
INR2, 3.4±0.88 vs 2.9±0.6 (p<0.0001). Compared to INR2, the mean variation
of INR3 during this second period was +16.1% (–29.6%, +114.4%). Finally
during Ramadan a VKA overdose was noted in 31.3% of cases. By multi-
variate analysis we found two independent predictors factors linked to a high
INR during Ramadan: an initial INR>3 before Ramadan (OR=3.57; p=0.037)
and a dose of acenocoumarol 4 mg (OR=3.5; p=0.041).
Conclusions: At our knowledge this is the first study demonstrate that
intermittent fasting led to increase significantly the level of anticoagulation
during this holy period. After this pilot study, we recommend checking sys-
tematically the INR before and during this period in order to reduce the INR
around 2.
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Purpose: We aimed to assess the long term prognosis associated with
COPD in a contemporary large cohort of pts with established CAD.
Methods: 783 consecutive male pts hospitalized in 2001-2004 for coro-
nary artery disease were considered. The median follow-up was 7.17 years.
Total mortality was predicted with a Cox proportional hazard model.
Results: Mean age (SD) was 60.2 (8.1), 144 pts (18.4%) were diabetic,
mean glycaemia was 5.9 mmol/l (2.1), 155 pts (19.8%) were smokers, mean
blood pressure was 139 (20)/84 (11) mmHg and median heart rate was 61 bpm
[Interquatile range (IQR)] [57-70]. Mean HDL cholesterol was 43 mg/dl (11),
mean LDL cholesterol 124 mg/dl (39) and median triglycerides were 147 mg/dl
IQR [109-197]. Mean Cockcroft-Gault creatinine clearance was 87 ml/min
and 11 pts (1.4%) had a severe chronic renal failure (lower than 30 ml/min).
Mean left ventricular ejection fraction was 0.53 (0.13). 88.5% were on anti-
platelet therapy, 75.2% on beta-blocker, 66% on statin therapy and 54.8% on
ACE inhibitors or ARB.
A previous history of COPD was present in 3.5% of pts; 37% of them had
a beta-blocker therapy. The cumulative seven-year total mortality rate was
17.9% in the whole sample (51.8% in pts with COPD and 16.7% in those
without, p<0.001). Among COPD pts with beta-blocker therapy, the mortality
rate was 30% while mortality reached 64.7% in COPD pts without beta-
blocker (p=0.08).
After multivariate adjustment for age, diabetes, tobacco consumption
(none, 40 pack-years, >40 pack-years), heart rate, left ventricular ejection
fraction (>0.5;  0.5 and >0.35; 0.35), duration of CAD, ankle-brachial index
(>0.9; 0.9 and >0.6; 0.6), history of stroke, statin therapy and coronary
revascularization, hazard ratio for all-cause death was 2.22 (95% CI [1.15;
4.26] p=0.016) in pts with COPD compared to those without.
January 12th, Thursday 2012
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2012) 4, 54-66 55
Conclusion: Presence of a chronic obstructive pulmonary disease is asso-
ciated with a doubling risk of all-cause death in CAD pts.
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Introduction: In degenerative mitral regurgitation (MR), brain natriuretic
peptide (BNP) is a surrogate biomarker of the consequences of MR on the left
ventricle (LV) and left atrium (LA). LV global longitudinal strain (GLS),
quantified by 2-D speckle-tracking imaging (2DSt) improved the detection of
subclinical LV dysfunction. We aimed evaluating the impact of BNP on out-
come and its relationship with GLS, in asymptomatic patients with degenera-
tive MR.
Method and results: Comprehensive transthoracic echocardiography
including 2DSt quantification was performed in 135 consecutive asymptom-
atic patients with moderate to severe degenerative MR and preserved LV
function. BNP was correlated with age (r=0.28, p=0.009), indexed LV end-
systolic diameter (r=0.30, p=0.0006), indexed LA volume (r=0.51, p<0.0001),
E/Ea ratio (r=0.33, p<0.0001), systolic pulmonary pressure (r=0.24, p=0.006)
and GLS (r=–0.54, p<0.0001). On multiple regression analysis, only indexed
LA volume and GLS were independently associated with BNP (=1.1±0.4,
p=0.002 and =–6.6±1.4, p<0.001, respectively). According to the median of
BNP, patients with high BNP level had significant reduced event-free survival
(21±8% vs. 75±6%, p<0.0001). A GLS<23% was also associated with lower
event-free survival (85±6% vs. 33±7%, p<0.0001). In Cox multivariate anal-
ysis, after adjustment for age, sex, E/Ea ratio and indexed end-systolic diam-
eter, only indexed LA volume (hazard ratio [HR]=1.01, 95% confidence
interval [CI]: 1.0-1.3, p=0.036), GLS<23% (HR=3.3, 95% CI: 1.1-9.9,
p=0.03) and BNP<41 pg/ml (HR=3.5, 95%CI: 1.7-7.2, p=0.001) were inde-
pendent determinants of cardiac event-free survival.
Conclusion: In asymptomatic degenerative MR, LV longitudinal function
and LA volume are the main determinants of BNP release. BNP is a powerful
independent predictor of cardiac events. Assessment of plasma BNP level, LA
volume, and LV longitudinal function may help to improve risk stratification
and the management of these patients.
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Background: Detection of high-risk patients is an important issue for the
management of aortic valve stenosis (AS). Previous studies have shown that
plasma levels of BNP increases with AS severity and may provide prognostic
information. However, these studies were impeded by selection bias and inclu-
sion of relatively young patients, or their small sample sizes. In addition, a
wide overlap of BNP values between symptomatic and asymptomatic patients
was observed. Thus, the aim of the present study was to evaluate the prognosis
value of BNP in a cohort of elderly patients with AS.
Method: Nt-proBNP was measured at entry in the study and patients were
prospectively followed on a yearly basis. Inclusion criteria were age 70
years, at least mild AS, absence of symptoms, and absence of significant renal
insufficiency.
Results: 346 patients were included. Mean age was 79±6 years. 225 had
severe AS and 196 were symptomatic. Nt-proBNP increases with NYHA class
and hemodynamic parameters (p<0.0001). However, Nt-proBNP values were
widely scattered with a large overlap between symptomatic and asymptomatic
patients. Consequently, Nt-proBNP had poor sensibility and specificity for the
detection of patients with severe symptomatic AS (ROC curve =0.73, sensi-
tivity=47%, specificity=85%). Among the 150 asymptomatic patients, 12
underwent a prophylactic surgery and follow-up was in 126 (91%). Patients
with NT-proBNP<300 pg/ml had a better outcome than patients with Nt-
proBNP between 300 and 700 pg/ml, or >700 pg/ml (99% vs. 90% and 86%
event free survival at one year, p=0.004). However, Nt-proBNP was not an
independent predictor of outcome after adjustment for valve area, age and
gender (p=0.30).
Conclusion: Our study is the first to enhance the limits of Nt-proBNP for
the evaluation of AS patients. Our data show that Nt-proBNP is not an inde-
pendent prognostic factor of outcome and raises caution regarding a patients’
management based on BNP value especially in the elderly population.
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Objectives: The human matrix associated serine protease inhibitor “tissue
factor pathway inhibitor-2” (TFPI-2) is known to have inhibitory activity
towards matrix metalloproteases (MMPs), which play an important role in the
process of aortic valve stenosis (AS). Reduced synthesis of TFPI-2 has been
related to numerous pathophysiological processes such as atherosclerosis.
Since AS is an atherosclerosis-like process, we hypothesized that TFPI-2
might play a protective role in the progression of AS.
Methods: Calcified aortic valves (n=28) were obtained from patients
undergoing aortic valve replacement (16 men; 68.7±2.2 years;indexed aortic
valve area 0,42±0,03 cm²/m²). Valvular expression and localization of TFPI-2
and other components of atherosclerosis were evaluated by immunohis-
tochemistry. TFPI-2 expression was further analyzed using a home-made
ELISA and by Western blot. Finally, we evaluated TFPI-2 expression in pri-
mary valve myofibroblast cultures obtained from explanted valves after colla-
genase digestion (n=12).
Results: We demonstrated TFPI-2 expression in aortic valves, which was
found to be significantly lower in the calcified regions as compared to non cal-
cified zones (1705±266 vs 2997±433 pg/mg; p=0.001). In contrast, there was
an overexpression in calcified regions as compared to non calcified zones of
pro-atherosclerotic factors (tissue factor (837±131 vs 476±95 pg/mg; p=0.01)
and MMP9 (97±46 vs 38±7 pg/mg; p=0.04)) and pro-calcifying proteins
(osteopontin (46±11 vs 4.6±1.3 ng/mg; p<0.0005)). Finally we showed that
cultured valve myofibroblasts express variable amounts of TFPI-2, inducible
by IL-1 or TNF- stimulation. Baseline TFPI-2 expression seemed to be
inversely correlated to the degree of calcification of the valves.
Conclusion: We showed here for the first time, the presence of TFPI-2 in
calcified human aortic valves. The inverse correlation between TFPI-2 expres-
sion and valve calcification might suppose a protective role for TFPI-2 in
aortic valve disease.
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Purpose: Whether surgical or percutaneous, mitral commissurotomy is
hampered by late mitral restenosis. Percutaneous mitral commissurotomy
(PMC) can be used to treat restenosis. Series with long-term follow-up are
necessary to evaluate the usefulness of PMC in deferring surgery.
Methods: We studied 163 patients (pts) who underwent PMC because of
restenosis a mean period of 16±8 years after previous commissurotomy
